Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  6,8-bis(benzylthio)octanoic acid
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-11 of 11 for your search:
Start Over
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CL-CPI-613-022, NCT01520805
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CL-CPI-613-023, NCT01832857
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 22112, NCI-2012-02768, P30CA012197, NCT01768897
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase I
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 57112, NCI-2013-00674, P30CA012197, NCT01835041
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 57113, NCI-2013-00838, NCT01839981
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 28314, NCI-2014-01281, P30CA012197, NCT02168140
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 28114, NCI-2014-01280, P30CA012197, NCT02168907
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 59314, NCI-2014-01779, P30CA012197, NCT02232152
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI, Other
Protocol IDs: CCCWFU 59212, NCI-2013-00063, P30CA012197, NCT01766219
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 29113, NCI-2013-01312, P30CA012197, NCT01902381
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 years and older
Sponsor: NCI, Other
Protocol IDs: CCCWFU 62113, NCI-2013-01653, P30CA012197, NCT01931787
Start Over